A prospective study of Trimethoprime-sulfamethoxazole(TMP/SMX) for prevention of Pneumocystis pneumonia(PCP) in patients under immunosuppressive therapy

A prospective study of Trimethoprime-sulfamethoxazole(TMP/SMX) for prevention of Pneumocystis pneumonia(PCP) in patients under immunosuppressive therapy - Prevention study for PCP by TMP/SMX

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001647

Enrollment

Registered

2009-01-20

Start date

2008-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients with rheumatic diseases who are receiving more than 30mg/day of prednisolone

Interventions

Daily a week administration of a TMP/SMX(Bacter) tablet Twice a week administration of a TMP/SMX(Bacter) tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: In patients with rheumatic disease as follows: 1.From 20 to 75 years-old 2.Patients with informed consent 3.Patients received more than 30mg/day of prednisolone

Exclusion criteria

Exclusion criteria: 1.On TMP/SMX 2.Suffering from PCP 3.Complicated with serious liver and/or renal disfunction,cytopenia 4.Allergy to TMP/SMX 5.Pregnant,and/or nursing 6.In approppriate patients decided by doctors

Design outcomes

Primary

Measure	Time frame
Incidence of PCP	—

Secondary

Measure	Time frame
1)Positive rate of Pneumocystis polymerase chain reaction in sputum 2)Incidence of the increased plasma level of beta-D-gulucan	—

Countries

Japan

Contacts

Public ContactShinichi Kwai

Department of Internal Medicine, Toho University School of Mdicine, Tokyo,Japan Division of Rheumatology

skawai@med.toho-u.ac.jp03-3762-4151(ext.6591)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026